Akums Drugs & Pharmaceuticals share price today

Akums Drugs & Pharmaceuticals Ltd's share price was ₹734.95 at the close on 6 November 2026. It has been rising for 28 weeks. That is 13.5% above its average price over the last 200 trading days. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 46 weeks in a row.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Akums Drugs & Pharmaceuticals Ltd is in stage 2. The phase helps read everything below.

In the last 52 weeks it traded between ₹420 and ₹820, and at that close it sat 79% of the way up from that low.

Over the last 2.2 years the share price moved −8% while the NIFTY 500 moved −3%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: best operating margin in 13 quarters, foreign funds (FIIs) raised their stake for 3 quarters in a row and indian funds and insurers (DIIs) cut their stake for 3 quarters in a row.

1. Best operating margin in 13 quarters

   Operating margin was 15% in the June 2026 quarter, against 13% a year earlier.

   Why: The margin rose because the contract manufacturing business did more work, prices for its bulk drug ingredients recovered, and its factories were busier.

   Next results: check whether the contract manufacturing business keeps growing at the fast pace management expects in the September quarter.

   From the earnings call on 10 Aug 2026.

2. Foreign funds (FIIs) raised their stake for 3 quarters in a row

   From 1.1% to 4.5% of the company by the September 2026 quarter.

3. Indian funds and insurers (DIIs) cut their stake for 3 quarters in a row

   From 14.4% to 11.1% of the company by the September 2026 quarter.

For July to September 2026 (the quarter ended 30 September 2026), Akums Drugs & Pharmaceuticals reported revenue of ₹1,342 crore, up 31.8% from ₹1,018 crore a year earlier, and a profit of ₹115 crore, up 167.4% from ₹43.0 crore.

Akums Drugs & Pharmaceuticals results: July to September 2026 against a year earlier

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

The newest call in our records is from 10 August 2026, about April to June 2026; a call about these results is not in our records yet.

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

Akums Drugs & Pharmaceuticals closed at ₹734.95 on 6 November 2026, up 62.1% from ₹453.35 a year earlier (7 November 2025). Its highest weekly close since August 2024 was ₹1,066.65 on 16 August 2024.

Akums Drugs & Pharmaceuticals share price: then and now

Weekly closing prices. Each change is the move from that price to the 6 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

125 weekly closes from 9 August 2024 to 6 November 2026.

6 Nov 2026: Akums Drugs & Pharmaceuticals closed at ₹734.95, up 0.4% on the week and down 2.2% on the month. Results for July to September 2026: Revenue up 31.8% and profit up 167.4% on a year earlier.

Earlier

• 10 Aug 2026: Akums Drugs & Pharmaceuticals held its results call for April to June 2026. Management guided: CDMO volume growth at least in the high teens in Q2; overall company volume growth at least double digit in coming quarters.
• 3 Jul 2026: ex-date for a dividend + special dividend of ₹3 a share.

Akums Drugs & Pharmaceuticals paid ₹1 a share in regular dividends in the 12 months to 7 November 2026 (1 payment), a yield of 0.14% at the ₹734.95 close on 6 November 2026. The last was a dividend + special dividend of ₹3 a share, ex-date 3 July 2026.

Akums Drugs & Pharmaceuticals dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here.

Yes. Akums Drugs & Pharmaceuticals Ltd paid out 18% of its profit as dividends in FY26, and it paid a dividend in 1 of its last 9 reported years.

From the NSE corporate-actions record, read 7 November 2026.

On the call for April to June 2026, held on 10 August 2026, Akums Drugs & Pharmaceuticals' management guided: CDMO volume growth at least in the high teens in Q2; overall company volume growth at least double digit in coming quarters.

“At this point, it is not a question of whether we make a U-turn from here. It is about how we improve profitability and scale this business into a profitable venture.”Sahil Maheshwari, on the call for April to June 2026

What management guided

• CDMO FY27 operating margin expected in the 14-15% range; Q1 strength supports leaning toward the upper bracket.
• Branded formulations expected to return to growth in later quarters, with domestic performance improving after field-force expansion.
• Zambia to deliver $25 million, roughly ₹240 crore, in FY27 and similarly next financial year; Europe starts next financial year.
• Zambia and Europe operating margin expected similar to or slightly above current CRAMS high-teens levels.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for April to June 2026, 10 August 2026. The July to September 2026 results are out since, so this part may be out of date until we update it.

When Akums Drugs & Pharmaceuticals reports October to December 2026, these are the 3 checks that show whether the story is still on course. First: Zambia revenue recognition - check initial supply start, agreed government volumes and pricing, and early margin contribution.

Akums Drugs & Pharmaceuticals is on 2 of our India lists: Momentum stocks and Pharma stocks.

Akums Drugs & Pharmaceuticals Ltd earned ₹115 Cr of net profit in the Sep 2026 quarter, +167.4% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY26 profit was ₹256 Cr. Over 11 years profit has grown 17.6% a year on average. That is 8.6% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned ₹43.0 Cr. 1 of the last 12 reported quarters were loss-making.

For the full year, FY26 profit was ₹256 Cr (−25.6% on the year before).

Why profit moved: revenue changed +31.8% on a year earlier and the margin moved +6.0 percentage points. Most of the change came from keeping more of each sale.

On average over the last four quarters, profit changed +45.0% and revenue +17.6%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

Akums Drugs & Pharmaceuticals Ltd reported ₹1,342 Cr of revenue in the Sep 2026 quarter, +31.8% on the same quarter a year earlier. That is the 4th quarter in a row with growth on the year before. Over 11 years it has grown 10.4% a year on average. The last full year, FY26, came in at ₹4,359 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹4,827 Cr.

FY26 revenue was ₹4,359 Cr, +5.9% on the year before.

Recent pace: the last four quarters grew +17.6% on average, against 10.4% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +17.5%, against +8.8% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +12.7%, against +13.4% a year (stabilising).

Akums Drugs & Pharmaceuticals Ltd's operating margin was 15.0% in the Sep 2026 quarter, 6.0 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 9 years it has been between −2.4% and 12.0%. The latest quarter is above every full year in that period.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +5.2 percentage points on the year while gross margin changed +1.1 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold.

Over the last 3 years, 357% of Akums Drugs & Pharmaceuticals Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹1,181 Cr of operating cash against ₹256 Cr of profit. After ₹228 Cr of spending on assets, ₹953 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 357% of profit came in as cash: the cash cycle stayed about the same between FY21 and FY26, so the cash follows profit, not the cycle.

What to look at next: the bigger use of cash is spending on new assets, at 2.0× depreciation over three years. The next section checks what that spending is building.

Akums Drugs & Pharmaceuticals Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 89 days in FY26, down from 90 days in FY21. It spent ₹867 Cr on assets over the last 3 years. Customers take 67 days to pay, and stock sits for 110 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹4,359 Cr, each day of that cycle ties up about ₹11.9 Cr, so roughly ₹1,063 Cr is tied up in the business at any time.

FY26: customers took 67 days to pay and stock sat for 110 days, about 3.6 months of sales sitting as stock, for a full cycle of 89 days, shorter than FY21's 90.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 110 days. Customers pay about 67 days after that. Suppliers are paid at 87 days. Together that makes the 89-day cycle.

Spending on assets: ₹867 Cr over the last 3 years, against ₹434 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹177 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Akums Drugs & Pharmaceuticals Ltd's P/E is 30.7×, in the middle of its own history: higher than 57% of past readings. Its usual P/E (the middle reading) is 27.2×, over 1 year of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹23.11.

Why the multiple is where it is: over the past year earnings per share moved −24.6% while the price moved +62.1%. The price did better than earnings, which pushed the multiple up within its own range.

In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple.

The PEG ratio and its quarterly curve, which only the second data source has, are not shown on this page: its two data sources disagree by up to 4.7% on reported income across 14 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data.

Akums Drugs & Pharmaceuticals Ltd's business is turning around. Profit growth has swung from −35.8% at its low to +167.4%, improving for 3 quarters in a row (from single-quarter figures), with ROCE falling at 15.0%. This is based on 10 quarters of 3 measures, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: a turn in growth is often where a bigger change starts. The lines say a turn is forming, so the question is whether the next quarters confirm it.

One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result.

The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone.

This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Akums Drugs & Pharmaceuticals Ltd earned a ROCE of 15% in FY26. That is up from a low of −16% in FY22. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a 5.9% net margin and 0.80× asset turnover (sales divided by assets).

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

Why the return is what it is (FY26): a 5.9% net margin × 0.80× asset turnover × 1.64× leverage (assets divided by equity) ≈ 7.7% on equity. The margin does its share; borrowing is a big part of it.

The quarterly return lines and the return-on-capital-used (ROIC) line, which only the second data source has, are not shown on this page: its two data sources disagree by up to 4.7% on reported income across 14 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data.

Akums Drugs & Pharmaceuticals Ltd had ₹157 Cr of borrowings against ₹3,314 Cr of equity in FY26, so its debt is 0.05× its equity. Its operating profit is 6 times its interest bill. Over 5 years borrowings went from ₹130 Cr to ₹157 Cr. Over the last 3 of those years it spent ₹867 Cr on assets.

Debt-to-equity shows how much of the business is paid for with borrowed money. Interest cover shows how many times operating profit pays the interest bill. Low debt and high cover are the safe combination.

Part of the spending on assets is being paid for with borrowed money.

The total-debt and debt-to-equity series, which only the second data source has, are not shown on this page: its two data sources disagree by up to 4.7% on reported income across 14 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data.

Domestic institutions raised their stake in Akums Drugs & Pharmaceuticals Ltd by 3.6 percentage points over 8 quarters, the biggest change among its owners. Domestic institutions now own 11.1% of the company. Foreign institutions moved −2.8 points over the same period, to 4.5%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.

Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.

Over the last two years: Domestic institutions: +3.6 points over 8 quarters, to 11.1%; Foreign institutions: −2.8 points over 8 quarters, to 4.5%; Promoters: +0.0 points over 8 quarters, to 75.3%.

Why the owners changed: foreign institutions moved −2.8 points and domestic institutions +3.6 points over 8 quarters, while promoters stayed about the same. One group of institutions took over shares from the other; it is not a change of mind by the people running the company.

For Akums Drugs & Pharmaceuticals Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

57.4 out of 100, rank 15 of 44 in Pharma - Formulators, with 75% of the evidence available.

Akums Drugs & Pharmaceuticals Ltd scores 57.4 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 15. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.

The four parts add up to the total exactly: 19.6 + 10.9 + 10.2 + 16.7 = 57.4. This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Akums Drugs & Pharmaceuticals ranks 15 of 44 Pharma - Formulators companies on the 4-Factor Sector Score, with 57.4 out of 100.

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.

Related companies: Pharma - Formulators, all 44 compared on one page.

Akums Drugs & Pharmaceuticals is the 24th largest of 44 Pharma - Formulators companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Natco Pharma, Corona Remedies and Marksans Pharma. Just below it: Strides Pharma Science, Suven Life Sciences and Bliss GVS Pharma.

Pharma - Formulators companies close in size

21. Natco Pharma Ltd ₹15,348 crore
22. Corona Remedies Ltd ₹14,593 crore
23. Marksans Pharma Ltd ₹14,242 crore
24. Akums Drugs & Pharmaceuticals Ltd ₹11,734 crore
25. Strides Pharma Science Ltd ₹9,851 crore
26. Suven Life Sciences Ltd ₹7,314 crore
27. Bliss GVS Pharma Ltd ₹6,663 crore

All 44 Pharma - Formulators companies, largest first

Companies close in size in other industries

537. Action Construction Equipment Ltd ₹11,845 crore · Capital Goods - EPC/Cranes
538. Vedanta Oil and Gas Ltd ₹11,821 crore
539. Akums Drugs & Pharmaceuticals Ltd ₹11,734 crore
540. Five-Star Business Finance Ltd ₹11,715 crore · Finance & Investments - MSME Lending
541. SKF India (Industrial) Ltd ₹11,709 crore · Bearings

Sector Alpha, written by code from the published numbers. Data as of 6 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.